US Biotech Reports Early Results on Drug to Sustain Weight Loss After GLP-1 Treatment

The announcement came via a post on social media from STAT News, a US health and science publication, flagging that Enveda — a biotechnology firm based in Colorado — has produced initial results for a compound aimed at maintaining weight loss in people who have previously used GLP-1 drugs (glucagon-like peptide-1 receptor agonists, the class of medicines that includes widely known treatments such as semaglutide, sold under brand names including Ozempic and Wegovy).

GLP-1 medicines work by mimicking a hormone that regulates appetite and blood sugar. They have become some of the most talked-about drugs in medicine after trials showed significant weight loss in people with obesity. But a well-documented challenge is that much of the lost weight tends to return once patients stop taking them — and that’s the gap Enveda says its drug is designed to address.

These are preliminary results only. STAT News specifically noted that the drug should not be described as “exercise in a pill” — a phrase sometimes used loosely to describe compounds that mimic some physical effects of exercise at a cellular level. That framing, researchers and journalists have warned, risks setting expectations well beyond what early-stage data can support.

Enveda uses artificial intelligence to identify and develop molecules derived from plants. The company has not yet published full trial data in a peer-reviewed journal, and the results shared so far have not been independently verified by regulators such as the US Food and Drug Administration or the European Medicines Agency.

For Kent residents currently taking GLP-1 medicines prescribed through NHS Kent and Medway, nothing about this announcement changes current treatment. Any questions about weight management medicines or stopping a prescribed treatment should go to a GP or pharmacist — not to early-stage research news.

For general health queries, NHS 111 is available online or by phone, 24 hours a day.